DR. MED. PHILIPP KICKINGEREDER, MD MBA

GENERAL INFORMATION

Nationality: Austrian

Heidelberg University Hospital
Department of Neuroradiology

ACADEMIC EDUCATION & QUALIFICATION

2017-2018	Master of Business Administration (MBA) postgraduate studies at IE Business School, Madrid, Spain
2010-2013	Doctoral thesis (Dr. med.) at the University of Cologne, Germany
2006-2012	Medical studies (MD) at the Medical University of Innsbruck, Austria

PROFESSIONAL EXPERIENCE

since 2019	Research Group Leader for "Radiomics, Radiogenomics and Deep-Learning in Neuro-Oncology" in the Collaborative Research Centre SFB 1244 (Understanding and targeting resistance in glioblastoma – UNITE GLIOBLASTOMA) funded by the German Research Council (DFG)
since 2013	Radiologist and Research Group Leader for "Computational Imaging Analytics" at the Department of Neuroradiology, Heidelberg University Hospital (chair: Prof. Bendszus)
2012-2013	Postdoctoral researcher at the German Cancer Research Center (DKFZ) Heidelberg – Clinical Cooperation Unit Neuropathology (chair: Prof. von Deimling)

AWARDS, HONORS & FUNDING

2019	Semaan Family Foundation Pilot Grant (joint funding for a collaborative research between Heidelberg University Hospital and Massachusetts General Hospital, Boston, USA)
2018	EUROSTARS funding (through the national budgets of 36 EUREKA countries and by the European Union through Horizon 2020)
2017	Else-Kroener Memorial Scholarship of the Else Kroener-Fresenius Foundation
2016	Kurt-Decker-Prize of the German Society of Neuroradiology
2015	Physician-Scientist-Fellowship of the Medical Faculty of Heidelberg
2014	Marc-Duenzl-Prize of the German Society of Neuroradiology

PROFESSIONAL ORGANIZATIONS

European Organization for Research and Treatment of Cancer (EORTC - Brain Tumor Group), European Association of Neuro-Oncology (EANO), European Society of Neuroradiology (ESNR), German Society of Radiology (DRG)

KEY PUBLICATIONS

1. Kickingereder P, Isensee F, Tursunova I, Petersen J, Neuberger U, Bonekamp D, Brugnara G, Schell M, Kessler T, Foltyn M, Harting I, Sahm F, Prager M, Nowosielski M, Wick A, Nolden M, Radbruch A, Debus J, Schlemmer HP, Heiland S, Platten M, von Deimling A, van den Bent MJ, Gorlia T, Wick W, Bendszus M, Maier-Hein KH. Automated quantitative tumor response assessment of MRI in neuro-oncology with artificial neural networks: a multicenter, retrospective study. **Lancet Oncol.** 2019 May;20(5):728-740.
2. Tejada Neyra MA, Neuberger U, Reinhardt A, Brugnara G, Bonekamp D, Sill M, Wick A, Jones DTW, Radbruch A, Unterberg A, Debus J, Heiland S, Schlemmer HP, Herold-Mende C, Pfister S, von Deimling A, Wick W, Capper D, Bendszus M, Kickingereder P. Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. **Neuro Oncol**. 2018 Oct 9;20(11):1517-1524.

3. Kickingereder P, Neuberger U, Bonekamp D, Piechotta PL, Götz M, Wick A, Sill M, Kratz A, Shinohara RT, Jones DTW, Radbruch A, Muschelli J, Unterberg A, Debus J, Schlemmer HP, Herold-Mende C, Pfister S, Deimling AV, Wick W, Capper D, Maier-Hein KH, Bendszus M. Radiomic subtyping improves disease stratification beyond key molecular, clinical and standard imaging characteristics in patients with glioblastoma. **Neuro Oncol**. 2018 May 18;20(6):848-857
4. Kickingereder P, Götz M, Muschelli J, Wick A, Neuberger U, Shinohara RT, Sill M, Nowosielski M, Schlemmer HP, Radbruch A, Wick W, Bendszus M, Maier-Hein KH, Bonekamp D. Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response. **Clin Cancer Res**. 2016 Dec 1;22(23):5765-5771
5. Kickingereder P, Neuberger U, Bonekamp D, Piechotta PL, Götz M, Wick A, Sill M, Kratz A, Shinohara RT, Jones DTW, Radbruch A, Muschelli J, Unterberg A, Debus J, Schlemmer HP, Herold-Mende C, Pfister S, von Deimling A, Wick W, Capper D, Maier-Hein KH, Bendszus M: Radiomic subtyping improves disease stratification beyond key molecular, clinical and standard imaging characteristics in patients with glioblastoma. **Neuro Oncol.** 2017 [Epub ahead of print]
6. Kickingereder P, Bonekamp D, Nowosielski M, Kratz A, Sill M, Burth S, Wick A, Eidel O, Schlemmer HP, Radbruch A, Debus J, Herold-Mende C, Unterberg A, Jones D, Pfister S, Wick W, von Deimling A, Bendszus M, Capper D. Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. **Radiology**. 2016 Dec;281(3):907-918
7. Kickingereder P, Burth S, Wick A, Götz M, Eidel O, Schlemmer HP, Maier-Hein KH, Wick W, Bendszus M, Radbruch A, Bonekamp D. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models. **Radiology**. 2016 Sep;280(3):880-9
8. Kickingereder P, Radbruch A, Burth S, Wick A, Heiland S, Schlemmer HP, Wick W, Bendszus M, Bonekamp D.
1. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma. **Radiology**. 2016 May;279(2):542-52
9. Kickingereder P, Sahm F, Radbruch A, Wick W, Heiland S, von Deimling A, Bendszus M, Wiestler B. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. **Sci Rep**. 2015 Nov 5;5:16238.
10. Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. **Neuro Oncol**. 2015 Aug;17(8):1139-47